The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NSABP FC-9: Phase II study of dual immune checkpoint blockade (ICB) with durvalumab (D) plus tremelimumab (T) following palliative hypofractionated radiotherapy (SBRT) in patients (pts) with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) progressing on chemotherapy.
 
James J. Lee
Consulting or Advisory Role - Incyte; Loxo
Research Funding - Incyte; Merck
 
Greg Yothers
Employment - Mountainview Pediatrics (I)
Consulting or Advisory Role - Orbus Therapeutics; Pharmacyclics
 
Thomas J. George
Consulting or Advisory Role - Bayer; Merck
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Pharmacyclics (Inst); Tesaro (Inst)
 
Marwan Fakih
Honoraria - Sirtex Medical
Consulting or Advisory Role - Amgen; Array BioPharma; Genentech/Roche
Speakers' Bureau - Amgen; Taiho Pharmaceutical
Research Funding - Merck (Inst); Novartis (Inst)
 
Atrayee Basu Mallick
No Relationships to Disclose
 
Bassam Nabih Maalouf
No Relationships to Disclose
 
John C. Krauss
Research Funding - Abbvie (Inst); Abbvie (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Ignyta (Inst); OncoMed (Inst); Shire (Inst); Taiho Pharmaceutical (Inst); XBiotech (Inst)
 
Dwight Earl Heron
Stock and Other Ownership Interests - Cancer Treatment Services International (CTSI)
 
Carmen Joseph Allegra
Honoraria - Bristol-Myers Squibb (I)
 
Samuel A. Jacobs
No Relationships to Disclose